Venmax Drugs and Pharmaceuticals Ltd (VENMAX) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Venmax Drugs and Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Venmax Drugs and Pharmaceuticals Limited has submitted the Exchange a copy if Scrutinizer report along with voting results of court convened General Meeting held on October 24, 2026.
Court Convened Meeting · 27 Oct 2026, 12:39 am
Venmax Shareholders Approve Scheme of Amalgamation with Hatri Pharma Equity shareholders of Venmax Drugs and Pharmaceuticals Limited approved the Scheme of Amalgamation with Hatri Pharma Private Limited during the NCLT-convened meeting held on 24th Oct'26. The resolution passed with requisite majority, securing 99.9979% overall approval (72,10,542 votes in favor vs. 150 against across 72 voting members). Among public shareholders, votes in favor stood at 99.9976% (62,83,767 votes), comfortably meeting SEBI scheme requirements. Total votes polled represented 62.2527% of the company's 1,15,82,930 paid-up equity shares.
Venmax Drugs and Pharmaceuticals Limited has informed the Bombay Stock Exchange regarding Proceedings of court convened General Meeting held today i.e. October 24, 2026.
Court Convened Meeting · 24 Oct 2026, 9:11 pm
Venmax Drugs Convenes NCLT-Directed Shareholder Meeting for Hatri Pharma Amalgamation Venmax Drugs and Pharmaceuticals convened an NCLT-directed equity shareholders meeting on 24th Oct'26 to approve the Scheme of Amalgamation with Hatri Pharma Private Limited under Sections 230–232 of the Companies Act, 2013. The meeting followed an order dated 7th Sep'26 from the NCLT Hyderabad Bench-II. Shareholders were briefed on the scheme's rationale, valuation, and exchange ratios. Remote e-voting was conducted between 21st Oct'26 and 23rd Oct'26 alongside e-voting during the meeting; final voting results will be disclosed upon receipt of the Scrutinizer's Report.
Voting Results along with the Scrutinizers Report of the 37th Annual General Meeting of the Company held on 26th September 2026 through VC/OAVM.
Annual General Meeting · 28 Sept 2026, 7:59 pm
Summary of the proceedings of 37th Annual General Meeting of the shareholders held at 12.30 P.M. through video conferencing mode.
Annual General Meeting · 26 Sept 2026, 7:13 pm
Venmax Drugs and Pharmaceuticals Limited has informed exchange about the meeting of equity shareholders of the Company pursuant to the order passed by Hon. NCLT, Hyderabad bench II in respect ....
Court Convened Meeting · 23 Sept 2026, 3:43 am
Venmax Drugs and Pharmaceuticals Limited has informed the exchange about the update in respect of Scheme of Amalgamation of Hatri Pharma Private Limited (Amalgamating Company) with Venmax ....
Others (Uncategorized) · 08 Sept 2026, 7:43 pm
NCLT Directs Venmax Drugs Shareholder Meeting For Hatri Pharma Merger Venmax Drugs and Pharmaceuticals received an NCLT Hyderabad Bench order dated 7th Sep'26 regarding its composite scheme of amalgamation with Hatri Pharma Private Limited. NCLT directed Venmax to convene an equity shareholders' meeting on 24th Oct'26 at 12:30 PM via video conferencing, while dispensing with meetings for Hatri Pharma's shareholders and creditors of both entities. Under the proposed share exchange ratio, Venmax will allot 1 fully paid equity share (Rs 10 face value) for every 1 equity share held in Hatri Pharma.
Submission of Annual Report for the Financial Year 2025-26 Pursuant to Regulation 34 and other relevant provisions of the SEBI (Listing Obligations & Disclosure Requirements), 2015.
Others (Uncategorized) · 01 Sept 2026, 10:10 pm
Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, we would like to inform you that a meeting of Board of Directors of was held today i.e ....
Outcome · 31 Aug 2026, 10:57 pm
Venmax Drugs: Key Board Appointments and AGM Details Venmax Drugs' board, in its meeting on 31-Aug-26, has approved key leadership changes and AGM details. Venkata Rao Sadhanala has been elevated from Whole Time Director to Managing Director for 5 years, effective 11-Mar-26, with an annual remuneration of Rs. 30 lakhs. The 37th AGM is scheduled for 26-Sep-26 via video conference. The board also approved the regularization of Mrs. Padmaja Kalyani Sadhanala (spouse of the MD) as a Non-Executive Director and Mr. Revoor Ramachandra as a Non-Executive Independent Director.
Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/08/2026 ,inter alia, to consider and approve matters related ....
Intimation · 24 Aug 2026, 6:21 pm
Statement of Deviation & Variation for the Quarter ended June 30, 2026.
Others (Uncategorized) · 07 Aug 2026, 10:56 pm
Venmax Confirms No Deviation in Use of Preferential Issue Proceeds Venmax Drugs confirms no deviation in the utilization of proceeds from its preferential warrant issue for the quarter ended 30th Jun'26. The company aims to raise a total of Rs. 20.05 crores. So far, Rs. 12.69 crores have been received from the conversion of 63,44,000 warrants and Rs. 1.84 crores against 36,81,000 warrants. As of 30th Jun'26, Rs. 8.37 crores were utilized for working capital (of a total Rs. 10 crore allocation) and Rs. 0.20 crores for general corporate purposes. The disclosure was reviewed by the Audit Committee.
Unaudited Financial Results along with Limited Review Report for the Quarter ended June 30, 2026.
Financial Result · 07 Aug 2026, 10:35 pm
Venmax Forfeits Warrants, Reports Q1FY27 Profit Growth Venmax Drugs reported Q1FY27 (quarter ended 30th Jun'26) results and key corporate actions. Revenue grew 105% YoY to ₹247.94 lakhs, while net profit rose to ₹11.66 lakhs from ₹3.74 lakhs YoY. The Board also approved the forfeiture of 7,80,001 partly paid-up convertible warrants originally allotted on 20th Mar'25. This was due to non-payment of the balance ₹15 per warrant. Consequently, the company retained the initial subscription amount of ₹39 lakhs paid on these warrants, which now stand cancelled.
Unaudited Standalone Financial Results along with the Limited Review Report For the Quarter ended June 30, 2026.
Outcome · 07 Aug 2026, 10:26 pm
Venmax Forfeits Warrants, Reports Strong Q1FY27 Revenue Growth Venmax Drugs reported Q1FY27 revenue of ₹247.94 lakhs, a 104.9% YoY increase, with profit after tax turning to ₹11.65 lakhs from ₹3.74 lakhs YoY. Sequentially, revenue declined 37.1% QoQ. The Board also approved the forfeiture of 7,80,001 partly paid-up convertible warrants due to non-payment of the balance subscription amount. This action resulted in the company retaining the initial subscription amount of ₹39 lakhs. Basic EPS for the quarter stood at ₹0.10, up from ₹0.07 in the previous year's quarter.
Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve Unaudited ....
Intimation · 07 Aug 2026, 5:30 am
Venmax Board Meeting on Aug 7, 2026 to Approve Q1 Results Venmax Drugs and Pharmaceuticals will hold a Board Meeting on Aug 7, 2026, to consider and approve its un-audited financial results for the quarter ended Jun 30, 2026. The agenda also includes the potential forfeiture of partly paid-up share warrants. The trading window for designated persons, closed since Jul 1, 2026, will re-open on Aug 10, 2026, 48 hours after the results are declared.
Allotment of 7,53,334 Convertible warrants in to Equity Shares on Preferential basis pursuant to Regulation 30 read with schedule III of SEBI LODR Regulation, 2015.
Others (Uncategorized) · 30 Jul 2026, 9:45 pm
Venmax Allots 7.53 Lakh Equity Shares on Warrant Conversion On 30th Jul'26, Venmax Drugs' board approved the allotment of 7,53,334 equity shares to a non-promoter, Dinesh Muddu Kotian, upon conversion of an equal number of warrants. The shares, with a face value of Rs. 10, were issued at a price of Rs. 20 each, including a Rs. 10 premium. This allotment increased the company's paid-up capital to Rs. 14.48 crore. The company received Rs. 1.13 crore as the balance exercise price, representing 75% of the total issue price.
Allotment of 21,47,665 Convertible warrants in to Equity shares on preferential basis pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulation, 2015.
Others (Uncategorized) · 30 Jul 2026, 12:54 am
Venmax Allots 2.15 Million Equity Shares on Warrant Conversion On 29 Jul'26, Venmax Drugs approved the allotment of 21,47,665 equity shares to eight non-promoter warrant holders. The shares, with a face value of Rs. 10, were issued at a price of Rs. 20 each, following the conversion of an equal number of warrants. This action increased the company's paid-up equity capital to Rs. 13.73 crore, comprising 1,37,30,595 shares. The company received Rs. 3.22 crore as the balance exercise price. A total of 15,33,335 convertible warrants remain outstanding.
Statement of Deviation & variation for the Quarter and Year ended March 31, 2026.
Others (Uncategorized) · 15 May 2026, 7:43 pm
Venmax Drugs Confirms No Deviation in Use of Preferential Issue Proceeds Venmax Drugs confirms no deviation in the utilization of proceeds from its preferential issue for the quarter and year ended 31st Mar'26. The company raised funds on 20th Mar'25, with Rs. 12.69 crores received from warrant conversions and Rs. 1.84 crores against other warrants, out of a total planned raise of Rs. 20.05 crores. As of 31st Mar'26, Rs. 8.12 crores were utilized for working capital and Rs. 0.20 crores for general corporate purposes and acquisitions, fully in line with stated objectives.
Audited Financial Results for the Quarter and Year ended March 31 , 2026
Financial Result · 14 May 2026, 10:56 pm
VENMAX DRUGS AND PHARMACEUTICALS LIMITED. - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) ■ Revenue: 394 (+1085.1% YoY | +154.1% QoQ) ■ EBITDA: 1.3 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 0.3 (Loss to Profit YoY | Loss to Profit QoQ) ■ PAT: 10.7 (-86.2% YoY | +234.0% QoQ) ■ EPS (INR): 0.21 (-85.9% YoY | +250.0% QoQ)
Audited Financial Results for the Quarter and Year ended March 31, 2026
Outcome · 14 May 2026, 10:45 pm
VENMAX DRUGS AND PHARMACEUTICALS LIMITED. - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) ■ Revenue: 394 (+1085.1% YoY | +154.1% QoQ) ■ EBITDA: 1.3 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 0.3 (Loss to Profit YoY | Loss to Profit QoQ) ■ PAT: 10.7 (-86.2% YoY | +234.0% QoQ) ■ EPS (INR): 0.21 (-85.9% YoY | +250.0% QoQ)
Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Audited Standalone ....
Intimation · 14 May 2026, 5:30 am
Venmax Board Meeting on May 14 to Approve Q4 & FY26 Results Venmax Drugs and Pharmaceuticals Ltd. has scheduled a Board of Directors meeting for May 14, 2026, at 3:30 PM. The board will consider and approve the audited financial results for the quarter and year ended Mar 31, 2026. In connection with this, the trading window for designated persons, closed since Apr 1, 2026, will remain closed until May 16, 2026, which is 48 hours after the results are approved.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 14 Apr 2026, 9:59 pm
Venmax Confirms It Is Not Classified as a Large Corporate Venmax Drugs and Pharmaceuticals Limited announced on 14 Apr'26 that it does not meet the criteria to be classified as a 'Large Corporate' under SEBI regulations as of 31 Mar'26. Consequently, the company is not subject to the mandatory framework requiring large entities to raise funds through debt securities. The filing confirmed the company had outstanding borrowings of ₹0.00 Cr as of the last applicable reporting date and therefore holds no credit rating.
Disclosure under Regulation 31 (4) of SEBI (SAST) Regulations, 2011
Others (Uncategorized) · 06 Apr 2026, 5:33 pm
Venmax Drugs Promoters Declare Zero Encumbrance on Shareholding Venmax Drugs and Pharmaceuticals (BSE: 531015) disclosed on 06 Apr'26 that its Promoter Group holds zero encumbrance on their shares for the financial year ended 31 Mar'26. The filing, under SEBI (SAST) Regulations, included a specific declaration from promoter Venkat Narender Nuka, confirming his holding of 9,26,775 shares is completely unpledged. This annual declaration signals positive creditworthiness and financial stability within the promoter group, as none of their equity is pledged as collateral.
The Board has considered and approved the appointment of Mrs. Padmaja Kalyani Sadhanala as an Additional director, Non Executive and Non Independent Director and Mr. Revoor Ramachandra ....
Change in Management · 30 Mar 2026, 10:41 pm
Venmax Drugs Appoints Two New Directors to its Board Venmax Drugs announced two board appointments effective 30 Mar'26. Mrs. Padmaja Kalyani Sadhanala was named Additional Non-Executive, Non-Independent Director. She is the spouse of the Managing Director and has over 20 years of pharmaceutical industry experience. Mr. Revoor Ramachandra was appointed Additional Non-Executive, Independent Director for a five-year term. He brings over 42 years of experience from the Defence, Aerospace, and Automotive industries. Both appointments require shareholder approval at the next general meeting.
Approval of Modification of draft Scheme of Amalgamation submitted on November 12, 2025 between Hatri Pharma Private Limited (Transferor Company) and Venmax Drugs and Pharmaceuticals Limited ....
Others (Uncategorized) · 27 Mar 2026, 9:38 pm
Venmax Drugs Amends Merger Scheme to Revise Share Capital Venmax Drugs' Board approved a modification to its amalgamation scheme with Hatri Pharma on Mar 27, '26. The amendment revises the post-merger share capital structure. Consequently, the Issued, Subscribed, and Paid-up Capital will increase from Rs. 8,00,79,300 (80,07,930 shares) to Rs. 11,58,29,300 (1,15,82,930 shares). The number of convertible equity warrants pending allotment has been reduced from 72,56,000 to 36,81,000. Authorized capital remains unchanged at Rs. 22 crore. This change reflects the ongoing warrant conversion process.
Allotment of 28,00,000 Convertible warrants in to Equity shares on preferential basis and pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulations, 2015
Others (Uncategorized) · 23 Mar 2026, 9:23 pm
Venmax Allots 2.8M Equity Shares on Warrant Conversion On 23rd Mar'26, Venmax Drugs approved the allotment of 28,00,000 equity shares to two non-promoter warrant holders. The shares, with a face value of Rs. 10, were issued at a price of Rs. 20 each (including a Rs. 10 premium) upon conversion of an equal number of warrants. This preferential allotment raised Rs. 4.20 crore from the balance exercise price. Consequently, the company's paid-up share capital increased to Rs. 11.58 crore, comprising 1,15,82,930 equity shares.
Change in designation of Mr. Venkata Rao Sadhanala, whole Time director as Managing Director of the company for a period of 5 years w.e.f. March 11, 2026, subject to approval of shareholders.
Change in Management · 11 Mar 2026, 11:25 pm
Venmax Appoints New Managing Director from Existing Board Venmax Drugs & Pharmaceuticals has approved the change in designation of Mr. Venkata Rao Sadhanala from Whole Time Director to Managing Director. The appointment is effective 11 Mar'26 for a five-year term, concluding on 10 Mar'31. His remuneration is set at Rs. 30 lakhs per annum, including perquisites. This management change is subject to shareholder approval at the next General Meeting. Mr. Sadhanala is a Chartered Accountant and Company Secretary with over three decades of experience in finance, pharma, and M&A.